Robert L. Levin

Most-cited papers

1. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

   R. Buchanan, M. Davis, D. Goff, Michael F. Green +8 more

   2005Schizophrenia bulletin460 citations

   Semantic Scholar

   Save

2. Anti-PEG IgE In Anaphylaxis Associated with Polyethylene Glycol

   Zhao-Hua Zhou, C. Stone, B. Jakubovic, E. Phillips +6 more

   2020Journal of Allergy and Clinical Immunology: In Practice133 citations Open access

   Semantic Scholar

   Save

3. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

   Thomas Laughren, J. Gobburu, R. Temple, Ellis F. Unger +17 more

   2011Journal of Clinical Psychiatry80 citations

   Semantic Scholar

   Save

4. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

   T. Laughren, Robert L. Levin

   2006Schizophrenia bulletin80 citations Open access

   Semantic Scholar

   Save

5. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.

   Kimberley A Swank, E. Wu, C. Kortepeter, Jana Mcaninch +1 more

   2017Journal of the American Pharmacists Association46 citations

   Semantic Scholar

   Save

6. Food and Drug Administration commentary on methodological issues in negative symptom trials.

   T. Laughren, Robert L. Levin

   2011Schizophrenia bulletin42 citations Open access

   Semantic Scholar

   Save

7. Liver injury associated with dimethyl fumarate in multiple sclerosis patients

   M. Muñoz, C. Kulick, C. Kortepeter, Robert L. Levin +1 more

   2017Multiple Sclerosis31 citations

   Semantic Scholar

   Save

8. Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

   P. Schotland, Rebecca Racz, David Jackson, Robert L. Levin +2 more

   2018CPT: Pharmacometrics & Systems Pharmacology18 citations Open access

   Semantic Scholar

   Save

9. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting

   P. Schotland, Rebecca Racz, David B Jackson, Theodoros G. Soldatos +3 more

   2020Clinical pharmacology and therapy17 citations Open access

   Semantic Scholar

   Save

10. Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System

    Carmen Cheng, L. L. La Grenade, Ida-Lina Diak, A. Brinker +1 more

    2016Jornal de Pediatria10 citations Open access

    Semantic Scholar

    Save

11. Takotsubo Common Pathways and SNRI Medications.

    D. Woronow, Courtney M. Suggs, Robert L. Levin, Ida-Lina Diak +1 more

    2018JACC. Heart failure9 citations Open access

    Semantic Scholar

    Save

12. US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone.

    Vicky C Chan, L. L. La Grenade, Ida-Lina Diak, Robert L. Levin

    2015Journal of Clinical Psychiatry5 citations

    Semantic Scholar

    Save

13. Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

    Courtney M. Suggs, Robert L. Levin, A. Mosholder, Richard S. Swain +1 more

    2018Drug Safety1 citations

    Semantic Scholar

    Save

14. Acute Generalized Exanthematous Pustulosis in Association with Hydroxyzine and Cetirizine

    O. N. Nevo, L. L. La Grenade, Ida-Lina Diak, Robert L. Levin

    20171 citations Open access

    Semantic Scholar

    Save

15. Labeling and Drug Safety Communication Approaches to Loperamide Abuse.

    D. Woronow, Kimberley A Swank, E. Wu, C. Kortepeter +1 more

    2017JACC Clinical Electrophysiology0 citations Open access

    Semantic Scholar

    Save